A Special Edition Interview Program

The Current Application of and New Directions in Cancer Immunotherapy

FACULTY
David P McDermott, MD
Julie R Brahmer, MD

EDITORS
Neil Love, MD

CONTENTS
1 Audio CD

Track 1: Basic principles and tenets of cancer immunotherapy
Track 2: Current role of cytokines in the management of renal cell carcinoma (RCC)
Track 4: Results of a Phase II trial evaluating nivolumab for patients with metastatic RCC
Track 5: Clinical experience with and tolerability profiles of anti-PD-1/PD-L1 and anti-CTLA-4 therapies in RCC and melanoma
Track 6: Management of ipilimumab-associated colitis
Track 7: Duration of antitumor response and tolerability of anti-PD-1 and anti-PD-L1 immunotherapy
Track 8: Durable responses to anti-PD-L1 antibodies in melanoma, RCC and other solid tumors
Track 9: Incidence, severity and management of treatment-related pneumonitis with anti-PD-1 and PD-L1 antibodies
Track 10: Future incorporation of immune checkpoint inhibitors into the management of RCC
Track 11: Role of immunotherapy in metastatic melanoma with and without BRAF V600E mutations
Track 12: Activity and tolerability of ipilimumab in combination with nivolumab for patients with advanced melanoma
Track 13: High-dose interleukin-2 in the up-front management of metastatic RCC
Track 14: Investigation of anti-PD-L1 antibodies in combination with other systemic approaches in melanoma
Track 15: Up-front treatment decision-making for patients with BRAF mutation-positive metastatic melanoma
Track 16: Sequencing of immunotherapeutic options for BRAF-mutant metastatic melanoma
Track 17: Current and evolving data on pembrolizumab in melanoma
Track 18: Available research data and ongoing investigation of ipilimumab in non-small cell lung cancer (NSCLC)
Track 19: Potential combination of anti-PD-1 and anti-CTLA-4 antibodies in NSCLC
Track 20: Efficacy of anti-PD-1 antibodies in advanced NSCLC
Track 21: Potential integration of anti-PD-1/PD-L1 antibodies into the clinical care of patients with metastatic lung cancer
Track 22: Tolerability of anti-PD-1 agents in NSCLC
Track 23: Efficacy of anti-PD-L1 antibodies in lung cancer
Track 24: Responses to immune checkpoint inhibitors among patients with driver mutations
Track 25: Time to response with immune checkpoint inhibitors
Track 26: Incidence of “pseudoprogression” in patients receiving immune checkpoint inhibitors
Track 27: Challenges associated with the use of checkpoint inhibitors in the setting of small tumor burdens and low- or absent expression
Track 28: Contraindications to the use of checkpoint inhibitors
Track 29: Ongoing clinical trials of anti-PD-1 and anti-PD-L1 antibodies as monotherapy or in combination with other systemic approaches for patients with lung cancer
Track 30: Investigation of the immunosuppressive activity of various investigational agents and targeted therapies

Bonus Audio: Access approximately 1 hour of additional content available only on the web of ResearchToPractice.com/Immunotherapy15.
The Current Application of and New Directions in Cancer Immunotherapy

A Special Edition Interview Program

Neil Love, MD
Research To Practice
One Biscayne Tower
2 South Biscayne Boulevard, Suite 3600
Miami, FL 33131

Copyright © 2015 Research To Practice.
This activity is supported by educational grants from Bristol-Myers Squibb Company, Genentech BioOncology and Prometheus Laboratories Inc.

FACULTY
David F McDermott, MD
Julie R Brahmer, MD

EDITOR
Neil Love, MD

CONTENTS
1 Audio CD

Sponsored by Research To Practice.
Release date: April 2015
Expiration date: April 2016
Estimated time to complete: 2.5 hours

Interview with David F McDermott, MD

Track 1 Basic principles and tenets of cancer immunotherapy
Track 2 Current role of cytokines in the management of renal cell carcinoma (RCC)
Track 3 Differential mechanisms of action: Anti-PD-1/PD-L1 versus anti-CTLA-4 antibodies
Track 4 Results of a Phase II trial evaluating nivolumab for patients with metastatic RCC
Track 5 Clinical experience with and tolerability profiles of anti-PD-1/PD-L1 and anti-CTLA-4 therapies in RCC and melanoma
Track 6 Management of ipilimumab-associated colitis
Track 7 Duration of antitumor response and tolerability of anti-PD-1 and anti-PD-L1 immunotherapy
Track 8 Durable responses to anti-PD-L1 antibodies in melanoma, RCC and other solid tumors
Track 9 Incidence, severity and management of treatment-related pneumonitis with anti-PD-1 and PD-L1 antibodies
Track 10 Future incorporation of immune checkpoint inhibitors into the management of RCC
Track 11 Role of immunotherapy in metastatic melanoma with and without BRAF V600E mutations
Track 12 Activity and tolerability of ipilimumab in combination with nivolumab for patients with advanced melanoma
Track 13 High-dose interleukin-2 in the up-front management of metastatic RCC
Track 14 Investigation of anti-PD-L1 antibodies in combination with other systemic approaches in melanoma
Track 15 Up-front treatment decision-making for patients with BRAF mutation-positive metastatic melanoma
Track 16 Sequencing of immunotherapeutic options for BRAF-mutant metastatic melanoma
Track 17 Surgical resection: de-escalation in a multimodal era

Interview with Julie R Brahmer, MD

Track 18 Available research data and ongoing investigation of ipilimumab in non-small cell lung cancer (NSCLC)
Track 19 Potential combination of anti-PD-1 and anti-CTLA-4 antibodies in NSCLC
Track 20 Efficacy of anti-PD-1 antibodies in advanced NSCLC
Track 21 Potential integration of anti-PD-1/PD-L1 antibodies into the clinical care of patients with metastatic lung cancer
Track 22 Tolerability of anti-PD-1 agents in NSCLC
Track 23 Efficacy of anti-PD-L1 antibodies in lung cancer
Track 24 Efficacy of anti-PD-L1 antibodies in lung cancer
Track 25 Time to response with immune checkpoint inhibitors
Track 26 Incidence of “pseudoprogression” in patients receiving immune checkpoint inhibitors
Track 27 Challenges associated with the use of immune checkpoint inhibitors
Track 28 Contraindications to the use of checkpoint inhibitors
Track 29 Imaging clinical trials of anti-PD-1 Checkpoint inhibitors in combination with other systemic approaches for patients with lung cancer
Track 30 Investigation of immune checkpoint inhibitors in Hodgkin lymphoma

Bonus Audio:
Access approximately 1 hour of additional content available only on the web of ResearchToPractice.com/Immunotherapy15.

Bonus Audio Available Exclusively Online
Please visit ResearchToPractice.com/Immunotherapy15 for an additional 53 minutes of dialogue and discussion.

IU_15_1CD_BPack_Finalsi.indd   1
3/19/15   2:27 PM
841.48 KiB
OVERVIEW OF ACTIVITY
The past several years have seen an explosion in the emergence of new potential therapies that leverage the natural ability of the human body to attack and treat cancer. Known as immune-mediated therapies or cancer immunotherapies, these promising treatments are taking center stage at medical conferences and generating excitement all over the world. The future of immunotherapy may be more promising than ever imagined, as a number of novel approaches are already delivering unprecedented outcomes. However, with the many exciting advances that are rapidly occurring, a number of vexing questions and clinical challenges are emerging simultaneously. Featuring information on the latest research developments along with expert perspectives from clinical investigators, this CME program is designed to assist medical oncologists, hematology-oncology fellows and other allied cancer professionals to better understand the implications of emerging data and optimally incorporate existing and novel immunotherapeutic strategies into the care of patients with various cancers.

LEARNING OBJECTIVES
• Develop a basic understanding of the human immune response, and identify the underlying mechanisms by which various tumor types evade this process to proliferate and grow.
• Compare and contrast the mechanisms of action, efficacy and safety/toxicities of approved and investigational immunotherapies for the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and other solid tumors and hematologic cancers to determine the current and/or potential utility of each in clinical practice.
• Appreciate the recent FDA approvals of the anti-PD-1 antibodies pembrolizumab and nivolumab, and discern how these agents can be appropriately integrated into clinical practice for patients with metastatic melanoma.
• Counsel patients about and define supportive management strategies for immune-related adverse events and other common side effects associated with approved and developmental immunotherapeutics.
• Recall the scientific rationale for ongoing investigations of novel immunotherapeutic approaches, and counsel appropriately selected patients about study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY
This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the CD and bonus web-only audio, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located in the back of this booklet or on our website at ResearchToPractice.com/Immunotherapy15/CME.

This activity is supported by educational grants from Bristol-Myers Squibb Company, Genentech BioOncology and Prometheus Laboratories Inc.

Release date: April 2015; Expiration date: April 2016
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
The Current Application of and New Directions in Cancer Immunotherapy

QUESTIONS (PLEASE CIRCLE ANSWER):

1. A Phase II trial reported by Motzer and colleagues evaluating 3 different doses of __________ demonstrated durable response rates with a manageable safety profile in patients with metastatic renal cell carcinoma.
   a. Nivolumab
   b. Pembrolizumab
   c. MPDL3280A

2. Adverse events associated with immune checkpoint inhibitors include ____________.
   a. Fatigue
   b. Decreased appetite
   c. Fever
   d. Diarrhea
   e. Skin reactions
   f. All of the above

3. Responses to anti-PD-L1 antibodies have been reported in patients with ____________.
   a. Bladder cancer
   b. Melanoma
   c. Non-small cell lung cancer
   d. Renal cell carcinoma
   e. All of the above

4. ____________ is an anti-PD-1 antibody that was recently approved for the treatment of unresectable or metastatic melanoma with disease progression after ipilimumab (if the patient has BRAF mutation-negative disease) or both ipilimumab and a BRAF inhibitor (if the patient has BRAF V600 mutation-positive disease).
   a. Pembrolizumab
   b. Nivolumab
   c. Both a and b
   d. Neither a nor b

5. Trials evaluating single-agent nivolumab in patients with metastatic melanoma have demonstrated activity with this agent in patients with ____________ disease.
   a. Ipilimumab-naive
   b. Ipilimumab-refractory
   c. Both a and b
   d. Neither a nor b

6. Data published by Wolchok and colleagues evaluating the combination of nivolumab and ipilimumab reported that the combination produced higher response rates than those reported previously with nivolumab monotherapy.
   a. True
   b. False

7. A Phase II study published by Lynch and colleagues evaluating ipilimumab in combination with paclitaxel and carboplatin as first-line therapy for Stage IIIIB/IV non-small cell lung cancer reported significant improvements in progression-free survival for patients with ____________ histology.
   a. Nonsquamous
   b. Squamous
   c. Both a and b
   d. Neither a nor b

8. Responses to anti-PD-1/PD-L1 antibodies are ____________ among smokers compared to never smokers.
   a. Greater
   b. Lesser
   c. Equivalent
The Current Application of and New Directions in Cancer Immunotherapy

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART 1 — Please tell us about your experience with this educational activity

How would you characterize your level of knowledge on the following topics?

<table>
<thead>
<tr>
<th>Topic</th>
<th>BEFORE</th>
<th>AFTER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy and safety of anti-PD-1 and anti-PD-L1 antibodies in metastatic renal cell carcinoma, melanoma and non-small cell lung cancer</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Management of ipilimumab-associated colitis — best-practice use of corticosteroids, PCP prophylaxis and other immunosuppressive agents</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>FDA approvals of pembrolizumab and nivolumab and optimal integration into the management of metastatic melanoma</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Activity of ipilimumab in combination with anti-PD-1 antibodies in melanoma, renal cell carcinoma and non-small cell lung cancer</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Incidence, severity and management of treatment-related pneumonitis with anti-PD-1 and PD-L1 antibodies</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
</tbody>
</table>

Practice Setting:
- ☐ Academic center/medical school
- ☐ Community cancer center/hospital
- ☐ Group practice
- ☐ Solo practice
- ☐ Government (eg, VA)
- ☐ Other (please specify) ....................................................

Was the activity evidence based, fair, balanced and free from commercial bias?
- ☐ Yes
- ☐ No
- If no, please explain: ........................................................................

Please identify how you will change your practice as a result of completing this activity (select all that apply).
- ☐ This activity validated my current practice
- ☐ Create/revise protocols, policies and/or procedures
- ☐ Change the management and/or treatment of my patients
- ☐ Other (please explain): ........................................................................

If you intend to implement any changes in your practice, please provide 1 or more examples:
..................................................................................................................

The content of this activity matched my current (or potential) scope of practice.
- ☐ Yes
- ☐ No
- If no, please explain: ........................................................................

Please respond to the following learning objectives (LOs) by circling the appropriate selection:
- 4 = Yes
- 3 = Will consider
- 2 = No
- 1 = Already doing
- N/M = LO not met
- N/A = Not applicable

As a result of this activity, I will be able to:

- Develop a basic understanding of the human immune response, and identify the underlying mechanisms by which various tumor types evade this process to proliferate and grow. ........................................... 4 3 2 1 N/M N/A
- Compare and contrast the mechanisms of action, efficacy and safety/toxicities of approved and investigational immunotherapies for the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and other solid tumors and hematologic cancers to determine the current and/or potential utility of each in clinical practice. .................................................. 4 3 2 1 N/M N/A
- Appreciate the recent FDA approvals of the anti-PD-1 antibodies pembrolizumab and nivolumab, and discern how these agents can be appropriately integrated into clinical practice for patients with metastatic melanoma. .................. 4 3 2 1 N/M N/A
- Counsel patients about and define supportive management strategies for immune-related adverse events and other common side effects associated with approved and developmental immunotherapeutics. .......................... 4 3 2 1 N/M N/A
- Recall the scientific rationale for ongoing investigations of novel immuno-therapeutic approaches, and counsel appropriately selected patients about study participation. ........................................... 4 3 2 1 N/M N/A
Please describe any clinical situations that you find difficult to manage or resolve that you would like to see addressed in future educational activities:

Would you recommend this activity to a colleague?
☐ Yes ☐ No  If no, please explain: 

Additional comments about this activity:

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey.
☐ Yes, I am willing to participate in a follow-up survey.
☐ No, I am not willing to participate in a follow-up survey.

PART 2 — Please tell us about the faculty and editor for this educational activity

<table>
<thead>
<tr>
<th>Faculty</th>
<th>Knowledge of subject matter</th>
<th>Effectiveness as an educator</th>
</tr>
</thead>
<tbody>
<tr>
<td>David F McDermott, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Julie R Brahmer, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
</tbody>
</table>

Please recommend additional faculty for future activities:

REQUEST FOR CREDIT — Please print clearly

Name: ................................................................. Specialty: .................................................................

Professional Designation:
☐ MD  ☐ DO  ☐ PharmD  ☐ NP  ☐ RN  ☐ PA  ☐ Other  .................................................................

Street Address: ................................................................................................................. Box/Suite: .................................................................

City, State, Zip: .......................................................................................................................

Telephone: ................................................................. Fax: .................................................................

Email: .................................................................

Research To Practice designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be _________ hour(s).

Signature: ................................................................. Date: .................................................................

The expiration date for this activity is April 2016. To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/Immunotherapy15/CME.
The compact disc, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photo-copying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information and comparison with recommendations of other authorities.